Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
OptiBiotix Health Plc (OPTI.L)
York, GB
OptiBiotix Health Plc, a life sciences enterprise headquartered in York, United Kingdom, specializes in the discovery and advancement of microbiome-modulating technologies. The company formulates distinct microbial strains, innovative compounds, and tailored blends intended for integration into food products, nutritional supplements, and active ingredients. Their groundbreaking work aims to positively influence human physiology and yield substantial health benefits. Among its diverse product portfolio are Slimbiome, a natural ingredient for healthy and satiety-driven weight management, and SlimBiome Medical, a supplemental aid for weight control. Other offerings include CholBiome, a dietary supplement for maintaining healthy cholesterol; Lactobacillus plantarum LPLDL, a probiotic supporting cardiovascular health and overall well-being; LPGOS, a galactooligosaccharide utilized in food applications to mitigate cardiovascular risk factors and enhance general health; WellBiome, a functional fiber and mineral blend designed to bolster gut microbiome diversity and promote wellness; and Sweetbiotix, a sweetener for use in various foods and beverages. Ultimately, OptiBiotix's innovations are designed to prevent and manage prevalent chronic lifestyle diseases, including obesity, high cholesterol, and diabetes. The company was founded in 2012.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.46% | +8.70% | +27.55% | -1.57% | -19.35% | -7.41% | -51.17% | -25.15% | -87.86% | -92.47% | -99.82% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+34.0% ★ Q4'25: +107.8% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%-108.7% Q4'25: -1,152.4% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-104.0% Q4'25: +0.0% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-268.6% Q4'25: -278.3% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-59.7% Q4'25: -127.1% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+3.4% ★ Q4'25: +12.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q4'25: 0.00× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2016 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
|---|---|---|---|---|---|---|---|---|
| Revenue |
288.1K
est: 300.0K (-4.0%)
|
514.3K
est: 300.0K (+71.4%)
|
744.9K
est: 808.0K (-7.8%)
|
1.52M
est: 1.51M (+0.7%)
|
2.21M
est: 2.20M (+0.6%)
|
457.0K
est: 3.04M (-85.0%)
|
644.0K
est: 27.61M (-97.7%)
|
870.0K
est: 27.61M (-96.8%)
|
| EBITDA |
-1.40M
est: 60.0K (-2,436.7%)
|
-1.81M
est: 60.0K (-3,108.4%)
|
-1.68M
est: -4.27M (+60.5%)
|
6.31M
est: 302.6K (+1,984.1%)
|
6.51M
est: 440.0K (+1,380.2%)
|
2.75M
est: 607.6K (+352.3%)
|
-1.84M
est: 5.52M (-133.3%)
|
-2.06M
est: -5.52M (+62.8%)
|
| EBIT |
-1.52M
est: 60.0K (-2,626.7%)
|
-1.95M
est: 60.0K (-3,345.1%)
|
-1.90M
est: -4.76M (+60.1%)
|
6.06M
est: 302.6K (+1,902.3%)
|
6.23M
est: 440.0K (+1,314.8%)
|
2.52M
est: 607.6K (+315.4%)
|
-2.04M
est: 5.52M (-137.0%)
|
-2.27M
est: -5.52M (+59.0%)
|
| Net Income |
-1.30M
est: -1.37M (+5.3%)
|
-1.92M
est: -1.37M (-40.0%)
|
-2.37M
est: -4.08M (+41.9%)
|
5.80M
est: -1.25M (+563.0%)
|
6.26M
est: -1.55M (+504.8%)
|
2.59M
est: -1.29M (+300.2%)
|
-2.04M
est: 10.25M (-119.9%)
|
-1.81M
est: 10.60M (-117.0%)
|
| SGA |
1.24M
est: 409.4K (+203.3%)
|
1.71M
est: 409.4K (+317.2%)
|
2.17M
est: 1.10M (+97.1%)
|
906.7K
est: 2.06M (-56.1%)
|
1.10M
est: 3.00M (-63.5%)
|
994.0K
est: 4.15M (-76.0%)
|
1.81M
est: 37.68M (-95.2%)
|
651.0K
est: 49.65M (-98.7%)
|
| EPS |
-0.02
est: -0.01 (-19.3%)
|
-0.02
est: -0.01 (-66.4%)
|
-0.03
est: -0.02 (-24.7%)
|
0.07
est: -0.01 (+619.5%)
|
0.07
est: -0.02 (+552.5%)
|
0.03
est: -0.01 (+322.0%)
|
-0.02
est: 0.10 (-121.6%)
|
-0.02
est: 0.10 (-117.6%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Stephen Patrick O'Hara | Founder, Chief Executive Officer & Executive Director | 247.0K | male |
| Sofia Kolyda | Executive Director of Research & Development and Executive Director | 69.0K | — |
| David Jonathan Blain | Chief Financial Officer, Company Secretary & Director | — | male |
| Paul Cannings | Head of Operations & Quality | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for OPTI.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
